Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
MYGN's Cash to Debt is ranked higher than
98% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. MYGN: No Debt )
MYGN' s 10-Year Cash to Debt Range
Min: 16.5   Max: No Debt
Current: No Debt

Equity to Asset 0.88
MYGN's Equity to Asset is ranked higher than
93% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. MYGN: 0.88 )
MYGN' s 10-Year Equity to Asset Range
Min: 0.71   Max: 0.96
Current: 0.88

0.71
0.96
Interest Coverage No Debt
MYGN's Interest Coverage is ranked higher than
80% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. MYGN: No Debt )
MYGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 17.51
M-Score: -2.19
WACC vs ROIC
3.92%
30.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 29.21
MYGN's Operating margin (%) is ranked higher than
96% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. MYGN: 29.21 )
MYGN' s 10-Year Operating margin (%) Range
Min: -134.85   Max: 39.24
Current: 29.21

-134.85
39.24
Net-margin (%) 18.37
MYGN's Net-margin (%) is ranked higher than
95% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. MYGN: 18.37 )
MYGN' s 10-Year Net-margin (%) Range
Min: -89.39   Max: 42
Current: 18.37

-89.39
42
ROE (%) 19.43
MYGN's ROE (%) is ranked higher than
91% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. MYGN: 19.43 )
MYGN' s 10-Year ROE (%) Range
Min: -25.88   Max: 30.71
Current: 19.43

-25.88
30.71
ROA (%) 17.15
MYGN's ROA (%) is ranked higher than
96% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.94 vs. MYGN: 17.15 )
MYGN' s 10-Year ROA (%) Range
Min: -23.02   Max: 28.73
Current: 17.15

-23.02
28.73
ROC (Joel Greenblatt) (%) 243.74
MYGN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. MYGN: 243.74 )
MYGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -238.09   Max: 362.64
Current: 243.74

-238.09
362.64
Revenue Growth (3Y)(%) 31.50
MYGN's Revenue Growth (3Y)(%) is ranked higher than
99% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. MYGN: 31.50 )
MYGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 1.7   Max: 44.9
Current: 31.5

1.7
44.9
EBITDA Growth (3Y)(%) 27.00
MYGN's EBITDA Growth (3Y)(%) is ranked higher than
93% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. MYGN: 27.00 )
MYGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -10.6   Max: 47.2
Current: 27

-10.6
47.2
EPS Growth (3Y)(%) 26.90
MYGN's EPS Growth (3Y)(%) is ranked higher than
93% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. MYGN: 26.90 )
MYGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -16.6   Max: 66.6
Current: 26.9

-16.6
66.6
» MYGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MYGN Guru Trades in Q1 2014

John Griffin 1,000,000 sh (New)
Jean-Marie Eveillard 284,826 sh (New)
Chase Coleman 2,345,921 sh (+95.15%)
Steven Cohen 70,402 sh (+72.07%)
Richard Snow 1,817,401 sh (+18.11%)
First Pacific Advisors 251,100 sh (unchged)
Third Avenue Management Sold Out
Joel Greenblatt 1,206,099 sh (-8.37%)
Chuck Royce 9,435,713 sh (-12.98%)
Louis Moore Bacon 87,902 sh (-46.73%)
Jim Simons 62,800 sh (-82.69%)
Paul Tudor Jones 6,905 sh (-94.83%)
» More
Q2 2014

MYGN Guru Trades in Q2 2014

Andreas Halvorsen 1,330,294 sh (New)
John Burbank 16,676 sh (New)
Paul Tudor Jones 12,833 sh (+85.85%)
First Pacific Advisors 251,100 sh (unchged)
John Griffin Sold Out
Jean-Marie Eveillard Sold Out
Louis Moore Bacon Sold Out
Chuck Royce 9,299,478 sh (-1.44%)
Joel Greenblatt 1,117,351 sh (-7.36%)
Chase Coleman 1,900,000 sh (-19.01%)
Jim Simons 49,200 sh (-21.66%)
Richard Snow 1,091,227 sh (-39.96%)
» More
Q3 2014

MYGN Guru Trades in Q3 2014

Jim Simons 60,474 sh (+22.91%)
Chase Coleman 1,900,000 sh (unchged)
First Pacific Advisors 251,100 sh (unchged)
John Burbank Sold Out
Andreas Halvorsen Sold Out
Richard Snow 1,055,014 sh (-3.32%)
Chuck Royce 8,906,065 sh (-4.23%)
Joel Greenblatt 869,531 sh (-22.18%)
Paul Tudor Jones 7,976 sh (-37.85%)
» More
Q4 2014

MYGN Guru Trades in Q4 2014

Ken Fisher 88,333 sh (New)
Steven Cohen 360,300 sh (New)
Jim Simons 94,000 sh (+55.44%)
First Pacific Advisors 251,100 sh (unchged)
Chase Coleman 1,900,000 sh (unchged)
Paul Tudor Jones 6,518 sh (-18.28%)
Richard Snow 827,803 sh (-21.54%)
Joel Greenblatt 568,865 sh (-34.58%)
Chuck Royce 5,084,563 sh (-42.91%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Snow 2014-12-31 Reduce -21.54%0.3%$32.01 - $39.48 $ 34.79-2%827803
Joel Greenblatt 2014-12-31 Reduce -34.58%0.11%$32.01 - $39.49 $ 34.79-2%568865
Ken Fisher 2014-12-31 New Buy0.01%$32.01 - $39.48 $ 34.79-2%88333
Andreas Halvorsen 2014-09-30 Sold Out 0.23%$35.44 - $40.41 $ 34.79-7%0
Joel Greenblatt 2014-09-30 Reduce -22.18%0.12%$35.44 - $40.41 $ 34.79-7%869531
John Burbank 2014-09-30 Sold Out 0.01%$35.44 - $40.41 $ 34.79-7%0
Richard Snow 2014-06-30 Reduce -39.96%0.96%$33.1 - $42.21 $ 34.79-6%1091227
John Griffin 2014-06-30 Sold Out 0.38%$33.1 - $42.21 $ 34.79-6%0
Andreas Halvorsen 2014-06-30 New Buy0.23%$33.1 - $42.21 $ 34.79-6%1330294
Jean-Marie Eveillard 2014-06-30 Sold Out 0.03%$33.1 - $42.21 $ 34.79-6%0
John Burbank 2014-06-30 New Buy0.01%$33.1 - $42.21 $ 34.79-6%16676
John Griffin 2014-03-31 New Buy0.38%$20.79 - $38.17 $ 34.7914%1000000
Richard Snow 2014-03-31 Add 18.11%0.37%$20.79 - $38.17 $ 34.7914%1817401
Third Avenue Management 2014-03-31 Sold Out 0.13%$20.79 - $38.17 $ 34.7914%0
Jean-Marie Eveillard 2014-03-31 New Buy0.03%$20.79 - $38.17 $ 34.7914%284826
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.50
MYGN's P/E(ttm) is ranked higher than
94% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 19.50 )
MYGN' s 10-Year P/E(ttm) Range
Min: 9.09   Max: 80.49
Current: 19.5

9.09
80.49
Forward P/E 15.65
MYGN's Forward P/E is ranked higher than
95% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 15.65 )
N/A
PE(NRI) 19.50
MYGN's PE(NRI) is ranked higher than
93% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 19.50 )
MYGN' s 10-Year PE(NRI) Range
Min: 9.1   Max: 81.3
Current: 19.5

9.1
81.3
P/B 3.56
MYGN's P/B is ranked higher than
77% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. MYGN: 3.56 )
MYGN' s 10-Year P/B Range
Min: 1.89   Max: 8.23
Current: 3.56

1.89
8.23
P/S 3.58
MYGN's P/S is ranked higher than
73% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. MYGN: 3.58 )
MYGN' s 10-Year P/S Range
Min: 2.32   Max: 14.79
Current: 3.58

2.32
14.79
PFCF 31.06
MYGN's PFCF is ranked higher than
87% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 31.06 )
MYGN' s 10-Year PFCF Range
Min: 7.63   Max: 140.77
Current: 31.06

7.63
140.77
POCF 25.03
MYGN's POCF is ranked higher than
83% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 25.03 )
MYGN' s 10-Year POCF Range
Min: 7.21   Max: 43.85
Current: 25.03

7.21
43.85
EV-to-EBIT 10.65
MYGN's EV-to-EBIT is ranked higher than
95% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 10.65 )
MYGN' s 10-Year EV-to-EBIT Range
Min: -102.6   Max: 52.4
Current: 10.65

-102.6
52.4
PEG 0.86
MYGN's PEG is ranked higher than
98% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 0.86 )
MYGN' s 10-Year PEG Range
Min: 0.43   Max: 0.94
Current: 0.86

0.43
0.94
Shiller P/E 22.33
MYGN's Shiller P/E is ranked higher than
95% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 22.33 )
MYGN' s 10-Year Shiller P/E Range
Min: 14.42   Max: 502.6
Current: 22.33

14.42
502.6
Current Ratio 4.95
MYGN's Current Ratio is ranked higher than
87% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. MYGN: 4.95 )
MYGN' s 10-Year Current Ratio Range
Min: 2.2   Max: 20.28
Current: 4.95

2.2
20.28
Quick Ratio 4.59
MYGN's Quick Ratio is ranked higher than
87% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. MYGN: 4.59 )
MYGN' s 10-Year Quick Ratio Range
Min: 2.2   Max: 20.28
Current: 4.59

2.2
20.28
Days Inventory 41.61
MYGN's Days Inventory is ranked higher than
83% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 128.32 vs. MYGN: 41.61 )
MYGN' s 10-Year Days Inventory Range
Min: 22.14   Max: 48.67
Current: 41.61

22.14
48.67
Days Sales Outstanding 37.12
MYGN's Days Sales Outstanding is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 81.46 vs. MYGN: 37.12 )
MYGN' s 10-Year Days Sales Outstanding Range
Min: 9.44   Max: 90.17
Current: 37.12

9.44
90.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 40.45
MYGN's Price/Net Cash is ranked higher than
84% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 40.45 )
MYGN' s 10-Year Price/Net Cash Range
Min: 2.9   Max: 70.43
Current: 40.45

2.9
70.43
Price/Net Current Asset Value 10.64
MYGN's Price/Net Current Asset Value is ranked higher than
83% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 10.64 )
MYGN' s 10-Year Price/Net Current Asset Value Range
Min: 2.41   Max: 27.64
Current: 10.64

2.41
27.64
Price/Tangible Book 7.45
MYGN's Price/Tangible Book is ranked higher than
72% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.30 vs. MYGN: 7.45 )
MYGN' s 10-Year Price/Tangible Book Range
Min: 1.53   Max: 18.98
Current: 7.45

1.53
18.98
Price/DCF (Projected) 1.10
MYGN's Price/DCF (Projected) is ranked higher than
96% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 1.10 )
MYGN' s 10-Year Price/DCF (Projected) Range
Min: 0.64   Max: 22.85
Current: 1.1

0.64
22.85
Price/Median PS Value 0.55
MYGN's Price/Median PS Value is ranked higher than
95% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. MYGN: 0.55 )
MYGN' s 10-Year Price/Median PS Value Range
Min: 0.35   Max: 7.06
Current: 0.55

0.35
7.06
Price/Peter Lynch Fair Value 0.78
MYGN's Price/Peter Lynch Fair Value is ranked higher than
99% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 0.78 )
MYGN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.43   Max: 1.7
Current: 0.78

0.43
1.7
Price/Graham Number 2.48
MYGN's Price/Graham Number is ranked higher than
89% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. MYGN: 2.48 )
MYGN' s 10-Year Price/Graham Number Range
Min: 0.97   Max: 3.08
Current: 2.48

0.97
3.08
Earnings Yield (Greenblatt) 9.40
MYGN's Earnings Yield (Greenblatt) is ranked higher than
95% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. MYGN: 9.40 )
MYGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.9   Max: 22.7
Current: 9.4

1.9
22.7
Forward Rate of Return (Yacktman) 29.75
MYGN's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. MYGN: 29.75 )
MYGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.9   Max: 33.1
Current: 29.75

-19.9
33.1

Analyst Estimate

Jun15 Jun16
Revenue(Mil) 779 820
EPS($) 1.76 2.19
EPS without NRI($) 1.76 2.19

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:MYD.Germany,
Myriad Genetics Inc is a molecular diagnostic company, engaged in making a difference in patients lives through the discovery and commercialization of transformative tests which assess a persons risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. The Companys business segments include: research, molecular diagnostics and companion diagnostics. The research segment is engaged in the discovery of genes related to major common diseases and includes corporate services such as finance, human resources, legal, and information technology. The molecular diagnostics segment provides testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to ensure optimal treatment, or assess a patients risk of disease progression and disease recurrence. The companion diagnostics segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries. The Company offers nine commercial molecular diagnostic tests, including six predictive medicine tests, two personalized medicine tests, and one prognostic medicine test. The Company markets these tests through its sales force of approximately 400 people in the United States. It also markets BRACAnalysis, COLARIS, COLARIS AP, and Prolaris tests through its European sales force. The Companys competitors include other molecular diagnostic companies, diagnostic reference laboratories, large multi-national healthcare companies, and universities and other research institutions. The Company has 234 patents as well as patent applications in the United States and foreign countries. The patents and patent applications cover diagnostic biomarkers, genes, proteins, gene expression signatures, antibodies, primers, probes, assays, disease-associated genetic mutations and single-nucleotide polymorphisms, methods for determining genetic predisposition, methods for disease diagnosis, methods for determining disease progression, methods for correlation claims, and methods for disease treatment, and general molecular diagnostic techniques. The Companys U.S. patents relating to BRACAnalysis, COLARIS, COLARIS AP, MELARIS, PREZEON, PANEXIA and TruCulture also have related foreign issued patents in countries, including in Europe, Canada, Japan, Australia and New Zealand, claiming similar subject matter and having similar expiration dates. The services that the Company provides are regulated by federal, state and foreign governmental authorities.
» More Articles for NAS:MYGN

Headlines

Articles On GuruFocus.com
Chuck Royce Comments on Myriad Genetics Oct 08 2014 
Chuck Royce’s Royce Premier Fund Second Quarter 2014 Manager Commentary Oct 08 2014 
Why I Bought Myriad Genetics (MYGN) Apr 28 2014 
Scott Black, Delphi Management Recommends Stocks Nov 19 2013 
Surfing for Billionaire Bargains Sep 22 2013 
Baron Funds Comments on Myriad Genetics Inc. Jun 06 2013 
RS Investments' Value Fund First Quarter 2012 Mutual Fund Commentary Apr 17 2012 
Chuck Royce Buys Hawkins Inc., Myriad Genetics, and Fairchild Semiconductor Jul 07 2011 
Myriad Genetics Inc. Reports Operating Results (10-Q) May 05 2010 
Myriad Genetics Inc. (MYGN) CFO James S Evans sells 8,400 Shares Mar 12 2010 


More From Other Websites
Myriad RBM Launches New Immunoassay Services Based on the Ultrasensitive Simoa(TM) Platform Mar 05 2015
Myriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology Mar 04 2015
Myriad Publishes myPath(TM) Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology Mar 04 2015
Myriad Genetics to Present at the Barclays Global Healthcare Conference Mar 03 2015
Myriad Genetics to Present at the Barclays Global Healthcare Conference Mar 02 2015
What Falling Estimates & Price Mean for Myriad Genetics (MYGN) - Tale of the Tape Mar 02 2015
Heavy News Day For Several Biotech Stocks Feb 25 2015
Myriad Board Approves $200 Million Increase in Share Repurchase Program Feb 25 2015
Iridian bumps up position in Myriad Genetics Feb 17 2015
GeneDx, Inc. and its Parent BioReference Labs Announce Settlement of Their Cancer Gene Testing... Feb 17 2015
MYRIAD GENETICS INC Financials Feb 10 2015
Quest, Myriad Settle Patent Dispute on Breast Cancer Tests Feb 09 2015
Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation Feb 09 2015
10-Q for Myriad Genetics, Inc. Feb 06 2015
Myriad Genetics to Present at the 2015 Leerink Global Healthcare Conference Feb 06 2015
Myriad Genetics to Present at the 2015 Leerink Global Healthcare Conference Feb 06 2015
Myriad Genetics (MYGN) Stock Tumbling Today After Jefferies Price Target Reduction Feb 04 2015
Myriad Genetics Sinks 10% On Lowered Guidance, CEO Retirement Feb 04 2015
JMP Securities Upgrades Myriad Genetics, Says 'Revised Guidance Lowers The Bar' Feb 04 2015
Just How Bad Have Things Gotten at Myriad Genetics? Feb 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK